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Crimean-Congo hemorrhagic fever (CCHF) is a 
febrile hemorrhagic acute disease between ani-
mals and humans (Zoonoses), first reported in 
the Crimea, Ukraine, in 1944 and then in the 
Congo in 1954. Since then, the name of Crimean-
Congo has been used for the virus (1, 2). 
CCHF is endemic and outbreaks have been rec-
orded in many countries in Africa, the Middle 
East, Eastern Europe and Asia (3). The Crimean-
Congo hemorrhagic fever virus (CCHFV) causes 
disease and belongs to the genus Nairovirus from 
the family Bunyaviridae. The genome of this vi-
rus is a single-stranded RNA virus with a negative 
polarity (4).  
The CCHF disease can be transmitted via the bite 
of an infective adult tick, particularly Hyalomma 
marginatum or H. anatolicum and it can also be 
transmitted from infected animals and humans 
(4). 
The disease was accompanied by a mild fever in 
animals, improved by itself after a short fever, 
but the incubation period in humans is depend-
ent on the mode of transmission. As the incuba-
tion period in transmission via bites of infected 
ticks lasts between 1-3 days and this period in 
transmission through the blood and tissues takes 
6-12 days. 
Clinical manifestations of the disease include two 
stages: non-hemorrhagic and hemorrhagic stages. 
In the non-hemorrhagic stage, early symptoms of 
the disease including sudden onset of fever, 
weakness, severe pain in extremities, back pain, 
headache, anorexia, and photophobia were ob-
served. In the hemorrhagic and bleeding stage, 
the symptoms, including bleeding from the gums, 
nose, leg and hand skin, lung, stomach, and intes-
tine, usually appear four days after the onset of 
the disease. Severe leukopenia and thrombocyto-
penia can be seen particularly at this stage. The 
majority of the patients die from the shock, ane-
mia, excessive bleeding and disseminated intra-
vascular coagulation (DIC). The mortality rate of 
the disease is usually between 2% and 50% and 
the disease epidemic in hospital is more com-
mon, usually spread by contact with infected 
blood and body fluids or contaminated needles 
pushed through the skin (5-7).  
Rapid detection of the disease is necessary for 
monitoring and early treatment of the patients 
with specific antivirals such as ribavirin and sup-
portive measures, preventing hospital epidemics 
and bioterrorism attacks of the CCHF virus. To 
identify the suspected cases of CCHF, biosafety 
level 4 (BSL4) laboratories are needed. Because in 
these laboratories specific IgM and IgG antibod-
ies of the patients can be detected using the sero-
logical tests such as the ELISA method and also 
the isolation and sequencing of the genome can 
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be tested by the reverse transcriptase-polymerase 
chain reaction(RT-PCR) (7,8).  
Emergency personnel according to the emergen-
cy first aid priorities and before the official con-
firmation by the Arbovirus Laboratory of the 
Pasteur Institute and the Center for Infectious 
Diseases, Ministry of Health and Medical 
Education may attempt to treat patients without 
observing protective measures when dealing with 
the patients with the CCHF virus. Although the 
knowledge and awareness of the majority of phy-
sicians and nurses from the nature of the disease, 
modes of transmission and symptoms of the dis-
ease are relatively high, their knowledge is weak 
about the system of patient care, treatment of 
confirmed and suspected cases, as well as report-
ing of the cases of the disease.  
Some cases of this virus and hospital outbreaks 
were reported in our country and there is no cer-
tain vaccine for this disease, necessary protective 
measures, including wearing gloves, gowns, head 
coverings, shoe covers, face covers, mask N95, 
surgical mask and protective glasses should be 
observed when dealing with persons suspected of 
having the CCHF disease. Also, transport of in-
fectious specimens from suspected cases of the 
virus should be performed according to the par-
ticular protocol associated with the transport of 
high-risk infectious specimens (9,10). 
 
Conflict of interest  
 





1. Leblebicioglu H, Ozaras R, Irmak H, Sencan I 
(2016). Crimean-Congo hemorrhagic fever in 
Turkey: Current status and future challenges. 
Antiviral Res, 126(2):21-34. 
2. Whitehouse CA (2004). Crimean-Congo hemor-
rhagic fever. Antiviral Res, 64 (3): 145-160. 
3. Dowall SD, Buttigieg KR, Findlay-Wilson SJD, 
et al (2016). A Crimean-Congo hemorrhagic 
fever (CCHF) viral vaccine expressing nucle-
oprotein is immunogenic but fails to confer 
protection against lethal disease. Hum Vaccin 
Immunother, 12(2): 519-527. 
4. Zivcec M, Scholte EM F, Spiropoulou FC 
(2016). Molecular Insights into Crimean-
Congo Hemorrhagic Fever Virus. Viruses, 
8(4):106. 
5. Saghafipour A, Norouzi M, Zia Sheikholeslami 
N, et al (2012). Epidemiologic status of the 
patients with Crimean Congo Hemorrhagic 
Fever and its associated risk factors. Iran J Mil-
itary Med,14(1):1-5. 
6. Hamzeh pour S, Moradi M (2017). Clinical man-
ifestation and pathophysiology of Crimean-
Congo hemorrhagic fever on human. J Med 
Physiol, 2(2):32-33.  
7. Majidzadeh Ardabili K, Soleimani M, Gheilanchi 
Langrodi A (2011). Review on the Laboratory 
Diagnosis of Crimean-Congo Hemorrhagic 
Fever.  J Army Univ Med Sci, 9(4):275-284.  
8. Drosten C, Kümmerer MB, Schmitz H, Gün-
ther S (2003). Molecular diagnostics of viral 
hemorrhagic fevers. Antiviral Res, 57(1-2):61-
87.  
9. Sargolzaie N, DehghanHhaghighi J, Kharazmi F 
(2013). Crimean Congo Hemorrhagic Fever 
Surveillance and General Practitioners in 
Zahedan. Medical Journal of Mashhad University of 
Medical Sciences (MUMS), 56(1):21-25[In Per-
sian].  
10. Hassani Azad M, Abedi F, ChiniKar S, Bojdy A 
(2014). Effectiveness of safeguard measures 
in controlling a nosocomial outbreak of Cri-
mean-Congo hemorrhagic fever. Medical Jour-
nal of Mashhad University of Medical Sciences 
(MUMS), 57(4):616-621[Persian]. 
 
 
 
 
 
 
